New hope for kids with tough cancers: LAM561 trial launches

NCT ID NCT04299191

First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tests an experimental drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid cancers that have stopped responding to standard treatments. The goal is to find a safe dose and check for side effects. Up to 28 children will take the drug by mouth daily, starting with a low dose that may increase.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arkansas Children's Research Institute

    RECRUITING

    Little Rock, Arkansas, 72202, United States

    Contact Email: •••••@•••••

    Contact

  • Hackensack Meridian Health, Inc

    RECRUITING

    Edison, New Jersey, 08837, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Miami Hospital

    RECRUITING

    Miami, Florida, 33146, United States

    Contact

Conditions

Explore the condition pages connected to this study.